Loading organizations...
Loading organizations...
Serenno Medical develops a pioneering Urine Output (UO) Monitor designed for hospitalized patients to enhance the prediction of Acute Kidney Injury (AKI) and optimize fluid management. The system provides continuous UO measurement, which is crucial for early detection and assessment of AKI, enabling proactive intervention. Its design emphasizes automation, ease of use, and seamless integration with Electronic Medical Records (EMR), offering a hands-free and reliable solution for clinical environments.
The company was founded by Tomer Lark, who serves as CEO, and Noam Hadas, the CTO. Their foundational insight stemmed from recognizing Acute Kidney Injury as a prevalent, dangerous, and often avoidable complication impacting millions globally, which becomes difficult to treat once advanced. They identified that continuous monitoring of urine output is the most reliable method to detect and anticipate AKI, thereby offering a window for early and effective intervention.
Serenno Medical’s solution is intended for use with hospitalized patients across various settings, including emergency rooms, operating rooms, and intensive care units, with potential applications for remote and home-based care. The company’s vision centers on transforming kidney health by providing an early warning system that allows clinicians to detect kidney injury before it fully manifests, thereby preventing progression and improving patient outcomes.
Serenno Medical is an Israeli medtech startup founded in 2017 that develops the Sentinel device, a pioneering continuous urine output (UO) monitor for hospitalized patients.[1][2][3] The product automatically measures urine flow rate and volume in real time, enabling early detection of acute kidney injury (AKI)—a common, avoidable complication affecting 19 million patients annually—while integrating with existing hospital catheters and bags to reduce nursing workload and support fluid management in ICUs, ORs, and beyond.[1][2] It serves critically ill patients in high-stakes environments like ERs, ICUs, and remote/telehealth settings, solving the problem of late AKI detection by providing precise, actionable data via EMR connectivity, with over 96% accuracy demonstrated in a multicenter trial involving 40+ patients and 1,300+ hours.[1][2]
Backed by Alon Medtech Ventures and showing strong early validation, Serenno has raised over $5M in funding and plans commercial manufacturing post its 2020 FDA clearance target, positioning it for global adoption in kidney monitoring.[1][3][5]
Serenno Medical was co-founded in 2017 by Tomer Lark (CEO) and Noam Hadas (CTO), leveraging their expertise in medtech to address gaps in hospital patient monitoring.[1][2][3] The company emerged from Alon Medtech Ventures, owned by Dr. Shimon Eckhouse, a prominent investor in medical devices, which incubated Serenno as a portfolio company focused on innovative hospital monitoring solutions.[1][3] The flagship Sentinel idea stemmed from the need for reliable, real-time urine output tracking to predict AKI earlier than traditional methods, which often detect injury too late for intervention.[2]
Key early traction came from a successful multicenter clinical trial at Sheba and Rabin Medical Centers in Israel, validating the device's accuracy across diverse conditions like low/high urine flows, surgeries, and mobile beds—paving the way for commercialization.[1] The team, with over 70 years of combined medtech experience, includes COO Tamar Fleisher, VP R&D Sagie Meshulam, and clinical manager Tzlil Hershko, driving development from Israel with U.S. ties (e.g., advisor Daniel I. Sessler, MD from Cleveland Clinic).[2]
Serenno rides the wave of precision medicine and remote monitoring in critical care, where AKI remains a leading ICU killer despite affecting millions yearly—exacerbated by staffing shortages and delayed diagnostics.[2] Its timing aligns with post-pandemic shifts toward automated, telehealth-enabled devices that streamline workflows amid rising hospital demands and AKI awareness.[2] Market forces like aging populations, chronic kidney disease prevalence, and regulatory pushes for preventive tech (e.g., FDA pathways) favor non-invasive monitors like Sentinel, which synergize with existing infrastructure without high costs.[1]
By influencing AKI outcomes, Serenno contributes to the medtech ecosystem's focus on predictive analytics, potentially reducing complications for millions and setting benchmarks for fluid balance tech in global ICUs.[1][2][5]
Serenno Medical is poised for scale-up with commercial manufacturing underway post-clinical success, targeting FDA clearance (anticipated 2020) and expansion into U.S./global markets via its Alon Medtech backing and $5M+ funding.[1][5] Trends like AI-enhanced diagnostics, remote ICU proliferation, and value-based care will amplify its impact, evolving Sentinel into a multi-use platform for broader vital monitoring. As medtech shifts to proactive prevention, Serenno could redefine kidney health standards, delivering the early warnings that turn AKI from inevitable to preventable—echoing its origins in solving a silent hospital crisis.